Combination Therapy with Interferon Alfa-2b and Hydroxyurea during the Accelerated Phase of Chronic Myelogenous Leukemia

Bourantas, K. L.; Syrou, M.; Tsiara, Stavroula; Danella, M.; Konstantinides, P.

doi:10.1159/000203859

Cited by 5 publications

(2 citation statements)

References 7 publications

(13 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…IFNs have previously been shown to potentiate the cytotoxic effect of all chemicals tested in this study: HU [32,33], 5-FU [34,35], MTX [36] and cisPt [37,38]. Yonekura et al [39] have even proposed that Hsp27 plays a crucial role in the IFN-γ-induced sensitization of oral squamous cell carcinoma cells to anticancer drugs.…”

Section: Discussionmentioning

confidence: 84%

Antitumor Activity from the Combined Application of Poly(I:C) and Chemotherapeutics in Human Metastatic Pharyngeal Cell Lines

Matijević¹,

Kirinec²,

Pavelić³

2011

Chemotherapy

View full text Add to dashboard Cite

Background: Toll-like receptor 3 (TLR3) activation in tumor cells induces apoptosis. We investigated the effect of TLR3 ligand (poly(I:C)) in combination with chemotherapeutics applied to human pharyngeal carcinoma cells as a possible antitumor therapy. Methods:Human pharyngeal cancer cell lines were studied (FaDu and Detroit 562). Cytotoxicity assays and apoptosis assays (annexin V staining and caspase 3/7 activity measurements) were used to investigate the cytotoxic effects. By using TLR3 siRNA we confirmed that the observed effect is TLR3-dependent. Results: We found that the combined application of poly(I:C) and chemotherapeutics (cisPt, HU, 5-FU and MTX) has a stronger inhibitory effect on cell growth in tumor cells expressing functional TLR3 as compared with a single treatment. This is a result of TLR3-dependent apoptosis. Conclusion: Our study showed that a combined application of the two agents already being used in tumor therapy could lower the necessary dosage of chemotherapeutics, leading to fewer side effects.

show abstract

Section: Discussionmentioning

confidence: 84%

Antitumor Activity from the Combined Application of Poly(I:C) and Chemotherapeutics in Human Metastatic Pharyngeal Cell Lines

Matijević¹,

Kirinec²,

Pavelić³

2011

Chemotherapy

View full text Add to dashboard Cite

show abstract

“…40,[66][67][68]72,73,82,[84][85][86] However, it is generally not clear whether the case series was retrospectively defined -in which follow-up is, almost by definition, complete -or prospectively defined. Six studies do not report on length of follow-up 68,72,76,79,82 and, while the majority of studies (24) do report some measure of length of follow-up, this varies considerably.…”

Section: Attrition Biasmentioning

confidence: 99%

The effectiveness and cost-effectiveness of imatinib in chronic myeloid leukaemia: a systematic review

Garside

Round

Dalziel

et al. 2002

Health Technol Assess

View full text Add to dashboard Cite

Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per monograph and for the rest of the world £3 per monograph.You can order HTA monographs from our Despatch Agents:-fax (with credit card or official purchase order) -post (with credit card or official purchase order or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you either to pay securely by credit card or to print out your order and then post or fax it. Contact Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to Direct Mail Works Ltd and drawn on a bank with a UK address. Paying by credit cardThe following cards are accepted by phone, fax, post or via the website ordering pages: Delta, Eurocard, Mastercard, Solo, Switch and Visa. We advise against sending credit card details in a plain email. Paying by official purchase orderYou can post or fax these, but they must be from public bodies (i.e. NHS or universities) within the UK. We cannot at present accept purchase orders from commercial companies or from outside the UK. How do I get a copy of HTA on CD?Please use the form on the HTA website (www.hta.ac.uk/htacd.htm). Or contact Direct Mail Works (see contact details above) by email, post, fax or phone. HTA on CD is currently free of charge worldwide.The website also provides information about the HTA Programme and lists the membership of the various committees. HTAThe effectiveness and costeffectiveness of imatinib in chronic myeloid leukaemia: a systematic review R Garside NHS R&D HTA ProgrammeT he NHS R&D Health Technology Assessment (HTA) Programme was set up in 1993 to ensure that high-quality research information on the costs, effectiveness and broader impact of health technologies is produced in the most efficient way for those who use, manage and provide care in the NHS.The research reported in this monograph was commissioned by the HTA Programme on behalf of the National Institute for Clinical Excellence (NICE). Technology assessment reports are completed in a limited time to inform the appraisal and guidance development processes managed by NICE. The review brings together evidence on key aspects of the use of the technology concerned. However, appraisals and guidance produced by NICE are informed by a wide range of sources.The research reported in this monograph was funded as project number 01/26/01.The views expressed in this publication are those of the authors and not necessarily those of the HTA Programme, NICE or the Department of Health. The editors wish to emphasise that funding and publication of this research by the NHS should not be taken as implicit support for any recommendations made by the authors. Criteria for inclusion in the HTA monograph seriesReports are published in the HTA monograph series if (1) they have resulted from work commissioned for the HTA Programme, and (2) they are of a sufficiently high scientific quality as assessed by the referees and editors.Reviews in Hea...

show abstract

Novel biologic approaches to hematologic malignancies

Dutcher¹,

Wiernik²

Diagnostic and Therapeutic Advances in Hematologic Malignancies

View full text Add to dashboard Cite

Combination Therapy with Interferon Alfa-2b and Hydroxyurea during the Accelerated Phase of Chronic Myelogenous Leukemia

Cited by 5 publications

References 7 publications

Antitumor Activity from the Combined Application of Poly(I:C) and Chemotherapeutics in Human Metastatic Pharyngeal Cell Lines

Antitumor Activity from the Combined Application of Poly(I:C) and Chemotherapeutics in Human Metastatic Pharyngeal Cell Lines

The effectiveness and cost-effectiveness of imatinib in chronic myeloid leukaemia: a systematic review

Novel biologic approaches to hematologic malignancies

Contact Info

Product

Resources

About